Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

'Focused Ultrasound Drug Delivery - Where have we been and where are we going?'

Biographies

Dr Paul LyonDr Paul Lyon is a Specialty Registrar in Clinical Radiology within the Oxford University Hospitals NHS Foundation Trust with specialist interest in Interventional Oncology. Paul has an engineering background with degrees in Mathematics, Software Engineering & Bioinformatics and spent time in industry with IBM prior to completing a Graduate Entry Medicine degree in Nottingham. Paul completed higher surgical training at Charing Cross and Great Ormond Street hospitals before taking a General Surgical specialist registrar post in transplant and colorectal surgery in Merseyside. From 2013-2016, under a Biomedical Research Centre clinical research fellowship of the National Institute of Health Research (NIHR), Paul undertook his DPhil at the Nuffield Department of Surgical Sciences in close collaboration with the Institute of Biomedical Engineering, University of Oxford. During this time, he lead a first-in-man study exploring the safety, feasibility and efficacy of targeted chemotherapy using extracorporeal focused ultrasound in patients with liver metastasis (TARDOX Study). This study completed in 2017 and the subsequent key clinical papers have been highly cited worldwide, reflecting the great clinical potential for ultrasound-triggered drug delivery. Paul has since continued his research interests in therapeutic ultrasound and targeted drug delivery alongside his clinical training in Radiology. In addition, Paul has recently worked as the clinical fellow for the High Intensity Focused Ultrasound service, run under Prof. David Cranston (HIFU Clinical Director), and works closely with Prof. Wu (HIFU Consultant) in the ablation of uterine fibroids and other solid tumours using a Chinese extracorporeal ultrasound-guided focused ultrasound device.

Dr Laura SpiersDr Laura Spiers is a Specialist Registrar in Medical Oncology at the Churchill hospital (Oxford University Hospitals NHS Foundation Trust). She obtained her medical degree from the University of Cambridge, with an intercalated BA in Pharmacology. As a Clinical Fellow in the Oxford Early Phase Clinical Trials Unit, she has looked after patients with a range of cancers enrolled in dose escalation and expansion studies. She is currently undertaking a DPhil in Oncology, working with the Oxford Institute of Biomedical Engineering to lead the early phase clinical study (PanDox), investigating the role of ultrasound-mediated hyperthermia for enhanced drug delivery to unresectable pancreatic tumours. 

 

Professor Eleanor StrideProfessor Eleanor Stride is the Statutory Professor of Biomaterials in the Departments of Engineering Science and the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences. She specialises in Biomedical Ultrasound and the fabrication of nano and microscale devices for Targeted Drug Delivery. 

She obtained her BEng and PhD in Mechanical Engineering from University College London where she subsequently appointed to a Royal Academy of Engineering and Engineering and Physical Sciences Research Council (EPSRC) Research Fellowship. In 2011 she was awarded an EPSRC Challenging Engineering grant and joined the Biomedical Ultrasonics, Biotherapy and Biopharmaceutical Laboratory (BUBBL) in the Oxford Institute of Biomedical Engineering, where she became a full Professor in 2014. 

Her work has been recognized through the award of a Philip Leverhulme prize, The Royal Society Interface Award, Engineering Medal at the Parliamentary Science, Engineering & Technology for Britain awards, Acoustical Society of America Bruce Lindsay Award (2013), IET AF Harvey prize (2015), Blavatnik Awards for Young Scientists (2020). She was also made a fellow of the ERA foundation for her contributions to public engagement and promotion of Engineering, for example through the Born to Engineer series and documentaries for the BBC. She was nominated as one of the top 100 most influential Women in Engineering in 2016 and 2019, was made a fellow of the Royal Academy of Engineering in 2017, of the Acoustical Society of America in 2018, an honorary fellow of the IET in 2020 and an Officer of the Order of the British Empire in 2021.

She has published over 180 academic papers, 7 patents and is a director of 2 spin out companies set up to translate her research into clinical practice.

Constantin CoussiosProfessor Constantin Coussios is the Director of the Oxford Institute of Biomedical Engineering. He received his BA, MEng and PhD in Engineering from the University of Cambridge and was elected to the first statutory chair in Biomedical Engineering at the University of Oxford in 2011, with special responsibility for drug delivery and therapeutic devices. In 2017, he received the Silver Medal of the UK’s Royal Academy of Engineering for his contributions to organ preservation and ultrasound-enhanced drug delivery. In 2019, he was elected a Fellow of the Royal Academy of Engineering.

 

 

Chair: Professor Freddie Hamdy

All members of the University and NHS clinical staff are welcome.

 

Please email Louise King if you would like to attend.